ArticlePLoS pathogens2017
The redefinition of Helicobacter pylori lipopolysaccharide O-antigen and core-oligosaccharide domains.
Article in PLoS pathogens, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 55 citations in OpenAlex.
- Review
- Beyond Infection: Mitochondrial Reprogramming and Immunometabolic Adaptation inDiseases (Basel, Switzerland) · 2026Article
- CRISPR-based mutagenesis of lipopolysaccharide biosynthesis genes in Leptospira interrogans reveals gene essentiality and confirms the role of an O-antigen polymerase.Scientific reports · 2026Article
- Roles of the lipopolysaccharide biosynthesis-related geneVirulence · 2025Article
- Reinvestigation into the role of lipopolysaccharide Glycosyltransferases inGut microbes · 2025Article
- Insights into Functions of Universal Stress Proteins Encoded by Genomes of Gastric Cancer PathogenPathogens (Basel, Switzerland) · 2025Article
- Traditional Chinese medicine in the treatment ofWorld journal of gastroenterology · 2025Review
- Advances in Helicobacter pylori lipopolysaccharide structure and function.FEMS microbiology reviews · 2025Review
- High salt condition alters LPS synthesis and induces the emergence of drug resistance mutations inAntimicrobial agents and chemotherapy · 2024Article
- Galectin-2 AgglutinatesInternational journal of molecular sciences · 2024Article
- Probing the expression and adhesion of glycans involved in Helicobacter pylori infection.Scientific reports · 2024Article
- Review
- Lipopolysaccharide O-antigen profiles of Helicobacter pylori strains from Southwest China.BMC microbiology · 2023Article
- Dimethylaminododecyl Methacrylate-Incorporated Dental Materials Could Be the First Line of Defense againstInternational journal of molecular sciences · 2023Article
- Roles of Lipopolysaccharide Glycosyltransferases in Maintenance ofInternational journal of molecular sciences · 2023Article
- Lipopolysaccharide biosynthesis and traffic in the envelope of the pathogen Brucella abortus.Nature communications · 2023Article
- Role of AlgC and GalU in the Intrinsic Antibiotic Resistance ofInfection and drug resistance · 2023Article
- Simple and Rapid Endotoxin Recognition Using a Dipicolylamine-Modified Fluorescent Probe with Picomolar-Order Sensitivity.ACS omega · 2022Article
- Review
- Sweet impersonators: Molecular mimicry of host glycans by bacteria.Glycobiology · 2022Review
Corrections and comments
- Commented on by
Authors and funding
12 authors at 2 institutions in 3 countries.
Funding
Abstract
Helicobacter pylori lipopolysaccharide promotes chronic gastric colonisation through O-antigen host mimicry and resistance to mucosal antimicrobial peptides mediated primarily by modifications of the lipid A. The structural organisation of the core and O-antigen domains of H. pylori lipopolysaccharide remains unclear, as the O-antigen attachment site has still to be identified experimentally. Here, structural investigations of lipopolysaccharides purified from two wild-type strains and the O-antigen ligase mutant revealed that the H. pylori core-oligosaccharide domain is a short conserved hexasaccharide (Glc-Gal-DD-Hep-LD-Hep-LD-Hep-KDO) decorated with the O-antigen domain encompassing a conserved trisaccharide (-DD-Hep-Fuc-GlcNAc-) and variable glucan, heptan and Lewis antigens. Furthermore, the putative heptosyltransferase HP1284 was found to be required for the transfer of the third heptose residue to the core-oligosaccharide. Interestingly, mutation of HP1284 did not affect the ligation of the O-antigen and resulted in the attachment of the O-antigen onto an incomplete core-oligosaccharide missing the third heptose and the adjoining Glc-Gal residues. Mutants deficient in either HP1284 or O-antigen ligase displayed a moderate increase in susceptibility to polymyxin B but were unable to colonise the mouse gastric mucosa. Finally, mapping mutagenesis and colonisation data of previous studies onto the redefined organisation of H. pylori lipopolysaccharide revealed that only the conserved motifs were essential for colonisation. In conclusion, H. pylori lipopolysaccharide is missing the canonical inner and outer core organisation. Instead it displays a short core and a longer O-antigen encompassing residues previously assigned as the outer core domain. The redefinition of H. pylori lipopolysaccharide domains warrants future studies to dissect the role of each domain in host-pathogen interactions. Also enzymes involved in the assembly of the conserved core structure, such as HP1284, could be attractive targets for the design of new therapeutic agents for managing persistent H. pylori infection causing peptic ulcers and gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.